acetazolamide 250mg modified-release capsules
mercury pharma group ltd - acetazolamide - modified-release capsule - 250mg
acetazolamide 250mg tablets
waymade healthcare plc - acetazolamide - oral tablet - 250mg
acetazolamide 250mg tablets
crescent pharma ltd - acetazolamide - oral tablet - 250mg
acetazolamide 250mg tablets
waymade healthcare plc - acetazolamide - oral tablet - 250mg
acetazolamide 250mg tablets
accord-uk ltd - acetazolamide - oral tablet - 250mg
acetazolamide 250mg tablets
genesis pharmaceuticals ltd - acetazolamide - oral tablet - 250mg
acetazolamide 250mg tablets
teva uk ltd - acetazolamide - oral tablet - 250mg
valproate-aft sodium valproate 300 mg/3 ml solution for intravenous infusion or injection vials
aft pharmaceuticals pty ltd - sodium valproate, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic potassium phosphate; water for injections; nitrogen - valproate-aft is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible
valproate-aft sodium valproate 400 mg/4 ml solution for intravenous infusion or injection ampoules
aft pharmaceuticals pty ltd - sodium valproate, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: monobasic potassium phosphate; dibasic sodium phosphate dodecahydrate; water for injections; nitrogen - valproate-aft is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.
valproate-aft sodium valproate 1000 mg/10 ml solution for intravenous infusion or injection ampoules
aft pharmaceuticals pty ltd - sodium valproate, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: dibasic sodium phosphate dodecahydrate; nitrogen; water for injections; monobasic potassium phosphate - valproate-aft is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.